Reducing Tobacco Harm: Finding the Best Route for Africa

Aug.15.2022
Reducing Tobacco Harm: Finding the Best Route for Africa
Reducing tobacco harm is a public health strategy that advocates for harm reduction products as a practical approach to lower smoking rates.

The entire world agrees that smoking rates need to be decreased. Whether it's the ubiquitous cigarette or local cigars and hookahs known as shisha in Nigeria, all stakeholders want to reduce smoking rates, and in fact, keep reducing them. While cigarettes have always received the most attention, people are now beginning to recognize the dangers of shisha, especially as it becomes increasingly popular among young people.


However, the means to achieve the expected decrease in smoking rates continue to cause debate among various parties. The popular African saying, "there are different paths to reach the same destination" is a subtle way our ancestors chose to remind us that the destination is the ultimate goal. Naturally, as long as the expected destination or established objective is reached, everything is fair and great, without any mistakes made along the way.


In fact, this motto has never been more important than in the process of reducing smoking rates in Africa today. While the debate about the path to this destination continues, prohibitionists – those who believe that only complete abstinence from smoking can achieve a decrease in smoking rates – continue to denigrate advocates for harm reduction, while also denying the success of harm reduction plans.


The photo, taken by Haim Charbit on Unsplash, represents a public health strategy called tobacco harm reduction (THR), which aims to reduce personal and wider societal health risks associated with combustible tobacco products. This approach is based on the understanding that most of the harm related to combustible tobacco is caused by the chemical mixture released when tobacco is burned (smoked) and then inhaled. However, if you remove the smoking/burning element, the risk of consuming tobacco is significantly reduced.


THR advocates believe that many adult smokers who wish to quit smoking often struggle or cannot quit, while others wish to continue to enjoy nicotine without harmful effects. Therefore, these smokers should switch to alternative products that release nicotine without burning tobacco. The word "switching" is an effective term for THR advocates, who prioritize the freedom to switch and the availability of alternative options. Providing information on alternative or reduced-risk products is a key driver of effective THR strategies for adult consumers to make informed choices.


Recently, advocates of tobacco harm reduction (THR) have been promoting their cause in Africa by explaining the science behind the concept and citing successful records from countries that have accepted the ideology of reducing tobacco harm. It is worth noting that THR advocates still agree that quitting smoking is the best choice and frequently emphasize this fact. However, they have chosen a pragmatic approach because they understand that both quitting smoking and switching will achieve the goal of reducing smoking rates. The position of THR advocates is supported by scientific evidence from more developed economies, which recognizes that adopting and effectively implementing tobacco harm reduction strategies can significantly reduce smoking rates. For example, the United Kingdom has recognized the effectiveness of reducing tobacco harm or substituting tobacco products in lowering smoking rates. The National Institute for Health and Care Excellence (NICE), which publishes evidence-based guidelines for the most effective methods of disease prevention, diagnosis, and treatment, has also released guidelines for tobacco harm reduction. The guidelines acknowledge that quitting smoking is always the best choice for smokers, but they support the use of licensed nicotine-containing products (NCPs) to help smokers who are currently unable to quit transition to less harmful options.


The Food and Drug Administration (FDA) of the United States of America (USA) has begun to classify alternative products as "reduced-risk tobacco products". This is a clear indication that the country is relying on scientific and verified evidence to provide guidance on reducing tobacco harm.


According to reports, Japan's smoking rate has decreased by 34% primarily due to the introduction of alternative products that give citizens the opportunity to switch to lower-risk options rather than outright quitting. This was detailed in a report by renowned consultancy firm Frost & Sullivan in December 2020, which also emphasized the importance of establishing effective regulation.


In Canada, the government has released a scientifically-supported statement through the Canadian Ministry of Health, stating that "completely replacing smoking with e-cigarettes will reduce your exposure to harmful chemicals" and "e-cigarette products and e-cigarettes release nicotine in a smaller way than smoking." Others are advising adult smokers to stay away from combustible tobacco products. The Canadian Public Health Association also recognizes the efficacy of alternative products and has released statements since 2018 acknowledging that the risks associated with alternative nicotine delivery products are lower than combustible tobacco.


New Zealand's Ministry of Health launched a website called Vaping Facts in 2019 with the aim of educating citizens about the realities of using e-cigarettes as a smoking cessation tool. The website encourages smokers to consider e-cigarettes as a means of quitting smoking and widely disseminates content indicating that the risks associated with vaping are lower than with smoking. This is another clear example of a country using a scientific and fact-based approach to reduce the harm caused by tobacco.


African countries need to conduct independent evaluations of each potential pathway towards reducing smoking rates. Their health departments and other health organizations, including academic members, must commission independent research focused not only on reducing tobacco harm but also examining the numerous public health issues affecting their citizens. This will aid in determining the best policies and regulatory frameworks to effectively promote smoking cessation and reduce tobacco harm simultaneously.


Statement


This article is compiled from third-party information and is intended for industry professionals for communication and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is only for industry exchange and research purposes.


Due to limitations in the skill level of the translator, the translation may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government's positions and statements regarding domestic issues, as well as those concerning Hong Kong, Macau, Taiwan, and international relationships.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Juul Labs UK has introduced an upgraded JUUL2 Starter Kit for the UK market in October 2026, retaining a recommended retail price of £9.99 while doubling the number of included pods from two to four. The kit contains Crisp Menthol, Virginia Tobacco, Mango and Watermelon pods. The updated device replaces the previous proprietary charging dock with a USB-C port and offers longer battery life. The kit also features reduced packaging and retains a two-year limited warranty. Distribution is scheduled through major UK retailers, wholesalers, convenience stores and the JUUL UK website.
product
Oct.15
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York State will extend its tobacco products tax to “alternative nicotine products,” including tobacco-free nicotine pouches, from September 1, 2026, at a rate of 75% of the wholesale price. Distributors, wholesalers and retailers must also inventory products held as of 11:59 p.m. on August 31 and pay a floor tax. Vapor products are excluded from the new category and remain subject to New York's separate 20% supplemental sales tax on the retail price.
Aug.26
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22